viewZelira Therapeutics Ltd

Zelda Therapeutics attracts new managing director, Dr Richard Hopkins

The company has multiple medical cannabis research partners across the world.

medicinal cannabis
Zelda is focused on developing a range of cannabinoid-based formulations

Zelda Therapeutics Ltd (ASX:ZLD) has appointed experienced drug developer Dr Richard Hopkins as its managing director, effective today.

Dr Hopkins brings extensive knowledge and experience with his established track record in drug development of novel cancer therapies.

He also has strong experience with corporate strategy, business development and intellectual property matters.

Strategic focus on clinical validation of medicinal cannabis

Zelda’s new managing director Dr Richard Hopkins said: “I am excited to be joining Zelda Therapeutics at such a key point in the company’s development.

“I look forward to adding value to Zelda’s strategic direction and in particular leveraging revenue opportunities from the current clinical programs in the fast-growing medicinal cannabis sector.”

READ: Zelda Therapeutics progresses medicinal cannabis brain cancer research

Zelda is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions.

The company has a two-pronged strategy comprising:

• A human clinical trial programme focused on insomnia, autism and eczema with activities in Australia, Chile and the US; and
• A pre-clinical research program examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

Quick facts: Zelira Therapeutics Ltd

Price: 0.05 AUD

Market: ASX
Market Cap: $48.31 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...



Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

on 02/21/2020

2 min read